Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.
Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.
复制标题
实体器官受者的移植后淋巴增殖性疾病主要是宿主来源的侵袭性肿瘤。
DOI：
10.1093/ajcp/103.6.748
复制
发表时间：
1995
影响因子：
3.5
通讯作者：
Spiro,I
中科院分区：
文献类型：
--
作者：
Weissmann,DJ;Ferry,JA;Harris,NL;Louis,DN;Delmonico,F;Spiro,I
器官移植后免疫抑制的患者发生淋巴组织增生性疾病的频率增加，称为移植后淋巴组织增生性疾病（PTLD）。在骨髓同种异体移植的受者中，PTLD通常是供体来源的。只有少数发生于实体器官移植受者的淋巴瘤，其来源于宿主或供者淋巴细胞。作者分析了来自马萨诸塞州总医院的11例PTLD，其中7例男性和4例女性患者，年龄8 ~ 63岁，5例肾移植，4例心脏移植，2例肝移植。使用聚合酶链反应（PCR），调查在4号染色体上的D4 S174位点，13号染色体上的Rb 1.20位点，和19号染色体上的D19 S178位点的遗传多态性，只有一个肿瘤（以前报道）是供体来源，而10个是宿主来源。随访显示，6例患者死于PTLD，1例因复发PTLD存活，4例存活良好或死于其他原因，包括供体来源PTLD患者。基于这些病例和对既往报告病例的审查，作者得出结论，实体器官接受者中的大多数PTLD均为宿主来源。与供体来源肿瘤相比，在患有宿主来源肿瘤的实体器官接受者中，PTLD持续或复发的可能性似乎更大。
Patients immunosuppressed after organ transplantation have an increased frequency of lymphoproliferative disorders, known as posttransplantation lymphoproliferative disorders (PTLDs). In recipients of bone marrow allografts, PTLDs are often of donor origin. In only a few cases of lymphoma arising in solid-organ transplant recipients has the origin from host or donor lymphocytes been established. The authors have analyzed 11 cases of PTLD from Massachusetts General Hospital, arising in seven male and four female patients, aged 8 to 63, five with renal, four with cardiac, and two with hepatic allografts. Using the polymerase chain reaction (PCR) to investigate genetic polymorphism at the D4S174 locus on chromosome 4, the Rb1.20 locus on chromosome 13, and the D19S178 locus on chromosome 19, only one tumor (previously reported) was of donor origin, whereas 10 were of host origin. Follow-up revealed that six patients died of PTLD, one was alive with recurrent PTLD, and four were alive and well or had died of other causes, including the patient with donor-origin PTLD. Based on these cases and on a review of previously reported cases, the authors conclude that the majority of PTLDs in solid organ recipients are of host origin. There appears to be a trend toward a greater likelihood of persistent or recurrent PTLD among solid organ recipients with host-origin tumors than among those with donor-origin tumor.